MX2016009060A - Metodos y sistemas para determinar el riesgo de falla cardiaca. - Google Patents

Metodos y sistemas para determinar el riesgo de falla cardiaca.

Info

Publication number
MX2016009060A
MX2016009060A MX2016009060A MX2016009060A MX2016009060A MX 2016009060 A MX2016009060 A MX 2016009060A MX 2016009060 A MX2016009060 A MX 2016009060A MX 2016009060 A MX2016009060 A MX 2016009060A MX 2016009060 A MX2016009060 A MX 2016009060A
Authority
MX
Mexico
Prior art keywords
heart failure
methods
systems
determining risk
subject
Prior art date
Application number
MX2016009060A
Other languages
English (en)
Inventor
W Gerwien Robert
V Snider James
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Publication of MX2016009060A publication Critical patent/MX2016009060A/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan métodos, algoritmos, nomogramas y sistemas de computadora/software que se pueden utilizar para determinar con precisión el riesgo de desarrollar falla cardiaca dentro de un período de tiempo específico en un sujeto no diagnosticado o que presenta falla cardiaca. También se proporcionan métodos, algoritmos, nomogramas, sistemas de computadora/software para seleccionar un tratamiento para un sujeto y determinar la eficacia de un tratamiento para reducir el riesgo de falla cardiaca en un sujeto.
MX2016009060A 2014-01-10 2015-01-09 Metodos y sistemas para determinar el riesgo de falla cardiaca. MX2016009060A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925877P 2014-01-10 2014-01-10
PCT/US2015/010788 WO2015106081A1 (en) 2014-01-10 2015-01-09 Methods and systems for determining risk of heart failure

Publications (1)

Publication Number Publication Date
MX2016009060A true MX2016009060A (es) 2016-09-09

Family

ID=53521621

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009060A MX2016009060A (es) 2014-01-10 2015-01-09 Metodos y sistemas para determinar el riesgo de falla cardiaca.

Country Status (8)

Country Link
US (2) US20150199491A1 (es)
EP (1) EP3092488A4 (es)
JP (2) JP6655016B2 (es)
CN (2) CN113744876A (es)
AU (1) AU2015204675A1 (es)
CA (1) CA2935958A1 (es)
MX (1) MX2016009060A (es)
WO (1) WO2015106081A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
CN102533972B (zh) 2002-05-09 2014-07-02 布赖汉姆妇女医院 作为心血管病的标志和治疗靶的1l1rl-1
DK2848938T3 (da) 2006-04-24 2017-11-13 Critical Care Diagnostics Inc Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
PL2482078T3 (pl) 2006-05-01 2016-08-31 Critical Care Diagnostics Inc Diagnozowanie choroby sercowo-naczyniowej
EP2660599B1 (en) 2008-04-18 2014-09-10 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
EP3848394A1 (en) 2010-04-09 2021-07-14 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
ES2897419T3 (es) 2011-03-17 2022-03-01 Critical Care Diagnostics Inc Procedimientos de predicción del riesgo de un resultado clínico adverso
US8748110B2 (en) 2011-07-18 2014-06-10 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
JP6298466B2 (ja) 2012-08-16 2018-03-20 クリティカル ケア ダイアグノスティクス インコーポレイテッド 高血圧症を発症するリスクを予測するための方法
WO2014031764A1 (en) 2012-08-21 2014-02-27 Critical Care Diagnostics, Inc. Multimarker risk stratification
CN110868911B (zh) * 2017-04-29 2022-10-11 心脏起搏器股份公司 心力衰竭事件率评定
US10952681B2 (en) * 2017-09-05 2021-03-23 Medtronic, Inc. Differentiation of heart failure risk scores for heart failure monitoring
JP7024576B2 (ja) * 2018-04-20 2022-02-24 オムロンヘルスケア株式会社 電子血圧計および心不全検出器
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US20230128775A1 (en) * 2020-06-03 2023-04-27 Esn Cleer Biomarker identification for imminent and/or impending heart failure
GB202008994D0 (en) 2020-06-12 2020-07-29 Univ Edinburgh Assay method

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590200A1 (en) * 1992-10-02 1994-04-06 E.R. SQUIBB & SONS, INC. Device and method for the visualisation of cardiovascular risk factors
US5993388A (en) 1997-07-01 1999-11-30 Kattan; Michael W. Nomograms to aid in the treatment of prostatic cancer
US6409664B1 (en) 1997-07-01 2002-06-25 Michael W. Kattan Nomograms to aid in the treatment of prostatic cancer
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
JP2004537553A (ja) * 2001-07-19 2004-12-16 ファルマシア・コーポレーション アルドステロン受容体アンタゴニストおよびＨＭＧＣｏ−Ａレダクターゼ阻害剤の組合せ薬剤
US6881193B2 (en) * 2001-09-27 2005-04-19 Charlotte-Mecklenburg Hospital Non-invasive device and method for the diagnosis of pulmonary vascular occlusions
DK2848938T3 (da) 2006-04-24 2017-11-13 Critical Care Diagnostics Inc Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
WO2007143295A2 (en) 2006-04-27 2007-12-13 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
PL2482078T3 (pl) 2006-05-01 2016-08-31 Critical Care Diagnostics Inc Diagnozowanie choroby sercowo-naczyniowej
DK2019965T3 (en) 2006-05-02 2015-07-20 Critical Care Diagnostics Inc DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease
CA2659082A1 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
EP2240017B1 (en) * 2008-01-04 2019-03-13 Oxford University Innovation Limited Ketone bodies and ketone body esters as blood lipid lowering agents
EP2660599B1 (en) 2008-04-18 2014-09-10 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
CN102317790B (zh) * 2008-11-11 2014-12-10 B.R.A.H.M.S有限公司 Adm在制备用于评估心力衰竭和/或呼吸短促的制剂中的应用
EP3848394A1 (en) 2010-04-09 2021-07-14 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
CN108387744A (zh) 2010-08-26 2018-08-10 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
US20130280716A1 (en) 2010-11-10 2013-10-24 The Cleveland Clinic Foundation Ratio of apoa2 to HDLc or Equivalents thereof, Risk Markers for Cardiovascular Disease
WO2014031764A1 (en) * 2012-08-21 2014-02-27 Critical Care Diagnostics, Inc. Multimarker risk stratification

Also Published As

Publication number Publication date
AU2015204675A1 (en) 2016-07-28
CA2935958A1 (en) 2015-07-16
JP6995898B2 (ja) 2022-02-04
JP6655016B2 (ja) 2020-02-26
US20150199491A1 (en) 2015-07-16
JP2017512507A (ja) 2017-05-25
US20180018442A1 (en) 2018-01-18
EP3092488A4 (en) 2017-07-12
WO2015106081A1 (en) 2015-07-16
JP2020089746A (ja) 2020-06-11
EP3092488A1 (en) 2016-11-16
CN106461636A (zh) 2017-02-22
CN113744876A (zh) 2021-12-03

Similar Documents

Publication Publication Date Title
MX2016009060A (es) Metodos y sistemas para determinar el riesgo de falla cardiaca.
PH12017502153A1 (en) Diagnostic methods for t cell therapy
EP3177201C0 (en) SYSTEMS AND METHODS FOR ASSESSING NEURAL ACTIVITY IN THE EYE
SG10201807147TA (en) Verification methods and verification devices
GB2550524A (en) Selective reminders to complete interrupted tasks
GB2549406A (en) Methods for determining health risks
EP3120460A4 (en) Chips including classical and quantum computing processors
HK1231610A1 (zh) 用於無卡式交易處理的系統和方法
GB2559275B (en) Methods and systems for performing actions based on biometric data
EP3153092A4 (en) Pupil detection system, gaze detection system, pupil detection method, and pupil detection program
EP3186397A4 (en) Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
MX2016002879A (es) Sistemas, dispositivos y metodos para la terapia anti-tl1a.
PL3183701T3 (pl) Klient, platforma obliczeniowa, oraz sposoby przeprowadzania bezpiecznych transakcji
EP3173027A4 (en) Heart failure evaluation method and diagnosis device
PH12017500052A1 (en) Myo-inositol and probiotics and uses
TWD181120S (zh) 運算及控制單元之部分
HK1243786A1 (zh) 用於監視一個或更多個設施處的活動的系統和計算機實現的方法
EP3347844A4 (en) METHOD AND SYSTEM FOR DIAGNOSIS OF DISEASES AND FOR THE PREPARATION OF TREATMENT RECOMMENDATIONS
GB201502289D0 (en) Methods and systems for analyzing financial dataset
SG11201702806UA (en) Write request processing method, processor, and computer
WO2016004375A3 (en) Methods and materials for treating pain and depression
TW201614530A (en) Method for modeling a photoresist profile
AU358921S (en) Blood processing device
PH12017500084A1 (en) Vitamin b2 and its use
MX2016010948A (es) Composiciones y metodos para identificar neoplasias de celulas b sensibles a terapia de reduccion de celulas b.